Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
STSS vs SRTS vs ISRG vs NVCR vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
STSS vs SRTS vs ISRG vs NVCR vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $8K | $51M | $159.85B | $2.04B | $97.62B |
| Revenue (TTM) | $223K | $27M | $10.58B | $674M | $35.48B |
| Net Income (TTM) | $-723K | $-8M | $2.98B | $-173M | $4.61B |
| Gross Margin | -7.6% | 43.2% | 66.3% | 75.2% | 61.9% |
| Operating Margin | -40.9% | -37.5% | 30.5% | -27.2% | 17.9% |
| Forward P/E | — | — | 43.3x | — | 13.8x |
| Total Debt | $4M | $680K | $303M | $290M | $28.52B |
| Cash & Equiv. | $864K | $22M | $3.37B | $103M | $2.22B |
STSS vs SRTS vs ISRG vs NVCR vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Sharps Technology, … (STSS) | 100 | 0.0 | -100.0% |
| Sensus Healthcare, … (SRTS) | 100 | 43.6 | -56.4% |
| Intuitive Surgical,… (ISRG) | 100 | 188.1 | +88.1% |
| NovoCure Limited (NVCR) | 100 | 23.4 | -76.6% |
| Medtronic plc (MDT) | 100 | 73.0 | -27.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STSS vs SRTS vs ISRG vs NVCR vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STSS is the #2 pick in this set and the best alternative if growth is your priority.
- 99.1% revenue growth vs SRTS's -34.3%
SRTS is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.83, Low D/E 1.4%, current ratio 9.72x
- Beta 0.83, current ratio 9.72x
ISRG ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs NVCR's 38.5%
- PEG 1.99 vs MDT's 35.17
- 28.2% margin vs STSS's -324.8%
NVCR is the clearest fit if your priority is momentum.
- +2.6% vs STSS's -60.4%
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Better valuation composite
- Beta 0.42 vs STSS's 2.66, lower leverage
- 3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 99.1% revenue growth vs SRTS's -34.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs STSS's -324.8% | |
| Stability / Safety | Beta 0.42 vs STSS's 2.66, lower leverage | |
| Dividends | 3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +2.6% vs STSS's -60.4% | |
| Efficiency (ROA) | 175.8% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4% |
STSS vs SRTS vs ISRG vs NVCR vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
STSS vs SRTS vs ISRG vs NVCR vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
MDT leads 2 • STSS leads 0 • SRTS leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 159319.7x STSS's $222,722. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to STSS's -3.2%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $222,722 | $27M | $10.6B | $674M | $35.5B |
| EBITDAEarnings before interest/tax | -$8M | -$10M | $3.8B | -$165M | $9.4B |
| Net IncomeAfter-tax profit | -$723,347 | -$8M | $3.0B | -$173M | $4.6B |
| Free Cash FlowCash after capex | -$10M | $449,000 | $2.8B | -$48M | $5.4B |
| Gross MarginGross profit ÷ Revenue | -7.6% | +43.2% | +66.3% | +75.2% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -40.9% | -37.5% | +30.5% | -27.2% | +17.9% |
| Net MarginNet income ÷ Revenue | -3.2% | -28.1% | +28.2% | -25.7% | +13.0% |
| FCF MarginFCF ÷ Revenue | -44.2% | +1.6% | +26.8% | -7.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -62.2% | +23.0% | +12.3% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +111.0% | -3.0% | +18.8% | -100.0% | -11.9% |
Valuation Metrics
MDT leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.63x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $8,374 | $51M | $159.8B | $2.0B | $97.6B |
| Enterprise ValueMkt cap + debt − cash | $3M | $29M | $156.8B | $2.2B | $123.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -6.55x | 57.19x | -14.66x | 21.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.35x | — | 13.80x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.63x | — | 35.17x |
| EV / EBITDAEnterprise value multiple | — | — | 43.28x | — | 14.06x |
| Price / SalesMarket cap ÷ Revenue | — | 1.84x | 15.88x | 3.11x | 2.91x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.05x | 9.10x | 5.86x | 2.04x |
| Price / FCFMarket cap ÷ FCF | — | 152.72x | 64.18x | — | 18.83x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. SRTS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to STSS's 1.89x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs STSS's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.0% | -15.1% | +16.9% | -50.8% | +9.4% |
| ROA (TTM)Return on assets | -4.2% | -13.4% | +14.8% | -16.5% | +175.8% |
| ROICReturn on invested capital | -120.0% | -25.3% | +15.0% | -16.4% | +6.0% |
| ROCEReturn on capital employed | -153.7% | -19.7% | +16.5% | -28.9% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.89x | 0.01x | 0.02x | 0.85x | 0.59x |
| Net DebtTotal debt minus cash | $3M | -$21M | -$3.1B | $187M | $26.3B |
| Cash & Equiv.Liquid assets | $864,041 | $22M | $3.4B | $103M | $2.2B |
| Total DebtShort + long-term debt | $4M | $680,000 | $303M | $290M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -0.20x | — | — | -96.80x | 9.08x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $1 for STSS. Over the past 12 months, NVCR leads with a +2.6% total return vs STSS's -60.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs STSS's -92.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -10.7% | -24.9% | -19.9% | +36.4% | -20.0% |
| 1-Year ReturnPast 12 months | -60.4% | -31.1% | -16.4% | +2.6% | -5.5% |
| 3-Year ReturnCumulative with dividends | -100.0% | +3.4% | +48.5% | -74.2% | -6.3% |
| 5-Year ReturnCumulative with dividends | -100.0% | -4.0% | +61.7% | -90.2% | -29.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -47.4% | +549.2% | +38.5% | +24.3% |
| CAGR (3Y)Annualised 3-year return | -92.8% | +1.1% | +14.1% | -36.4% | -2.1% |
Risk & Volatility
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than STSS's 2.66 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 89.2% from its 52-week high vs STSS's 11.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.66x | 0.83x | 1.00x | 2.15x | 0.42x |
| 52-Week HighHighest price in past year | $18.23 | $5.92 | $603.88 | $20.06 | $106.33 |
| 52-Week LowLowest price in past year | $1.42 | $2.82 | $427.84 | $9.82 | $75.91 |
| % of 52W HighCurrent price vs 52-week peak | +11.0% | +52.0% | +74.5% | +89.2% | +71.6% |
| RSI (14)Momentum oscillator 0–100 | 54.8 | 50.8 | 43.6 | 70.9 | 29.2 |
| Avg Volume (50D)Average daily shares traded | 332K | 66K | 1.8M | 1.4M | 7.9M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ISRG as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 38.3% for ISRG (target: $623). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $622.60 | $33.50 | $109.50 |
| # AnalystsCovering analysts | — | — | 55 | 15 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.7% |
| Dividend StreakConsecutive years of raises | — | 2 | — | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.6% | +1.4% | 0.0% | +3.3% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
STSS vs SRTS vs ISRG vs NVCR vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STSS or SRTS or ISRG or NVCR or MDT a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -34. 3% for Sensus Healthcare, Inc. (SRTS). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STSS or SRTS or ISRG or NVCR or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 1. 99x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — STSS or SRTS or ISRG or NVCR or MDT?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +61. 7%, compared to -100. 0% for Sharps Technology, Inc. (STSS). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus STSS's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STSS or SRTS or ISRG or NVCR or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus Sharps Technology, Inc. 's 2. 66β — meaning STSS is approximately 527% more volatile than MDT relative to the S&P 500. On balance sheet safety, Sensus Healthcare, Inc. (SRTS) carries a lower debt/equity ratio of 1% versus 189% for Sharps Technology, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — STSS or SRTS or ISRG or NVCR or MDT?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -34. 3% for Sensus Healthcare, Inc. (SRTS). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -782. 0% for Sharps Technology, Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STSS or SRTS or ISRG or NVCR or MDT?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -324. 8% for Sharps Technology, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -40. 9% for STSS. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STSS or SRTS or ISRG or NVCR or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 1. 99x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 29. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.
08Which pays a better dividend — STSS or SRTS or ISRG or NVCR or MDT?
In this comparison, MDT (3.
7% yield) pays a dividend. STSS, SRTS, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is STSS or SRTS or ISRG or NVCR or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Sharps Technology, Inc. (STSS) carries a higher beta of 2. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, STSS: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STSS and SRTS and ISRG and NVCR and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: STSS is a small-cap quality compounder stock; SRTS is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while STSS, SRTS, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.